Clinical Trial Update: Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ibrutinib in patients with refractory or relapsed lymphoma after donor stem cell transplant completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blastoid Variant Mantle Cell Lymphoma
• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2023-01-20